Navigation

Pulmozyme (Genentech Inc)

Pulmozyme (Genentech Inc) - General Information

Recombinant human deoxyribonuclease I. Delivered by aerosol mist. The protein is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing DNA encoding for the native human protein, deoxyribonuclease I (DNase). 260 residues

 

Pharmacology of Pulmozyme (Genentech Inc)

Cystic fibrosis (CF) is a disease characterized by the retention of viscous purulent secretions in the airways. These thick secretions contribute both to reduced pulmonary function and to frequent pulmonary infection. Purulent pulmonary secretions contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to these infections. Pulmozyme (Genentech Inc) hydrolyzes the DNA in sputum of CF patients and reduces sputum viscoelasticity.

 

Pulmozyme (Genentech Inc) for patients

Pulmozyme must be stored in the refrigerator at 2�8°C (36�46°F) and protected from strong light. It should be kept refrigerated during transport and should not be exposed to room temperatures for a total time of 24 hours. The solution should be discarded if it is cloudy or discolored. Pulmozyme contains no preservative and, once opened, the entire contents of the ampule must be used or discarded. Patients should be instructed in the proper use and maintenance of the nebulizer and compressor system used in its delivery.

Pulmozyme should not be diluted or mixed with other drugs in the nebulizer. Mixing of Pulmozyme with other drugs could lead to adverse physicochemical and/or functional changes in Pulmozyme or the admixed compound.

 

Pulmozyme (Genentech Inc) Interactions

Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics. No formal drug interaction studies have been performed.

 

Pulmozyme (Genentech Inc) Contraindications

Pulmozyme is contraindicated in patients with known hypersensitivity to dornase alfa, Chinese Hamster Ovary cell products, or any component of the product.

 

Additional information about Pulmozyme (Genentech Inc)

Pulmozyme (Genentech Inc) Indication: For the treatment of cystic fibrosis.
Mechanism Of Action: Pulmozyme (Genentech Inc) hydrolyzes DNA, thereby degrading large, viscous DNA molecules into small, soluble fragments that are easily cleared from the lungs.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Dornase Alfa
Synonyms: DNase I; Deoxyribonuclease I; Deoxyribonuclease-1 precursor; Dornase alfa; DNase; rhDNase
Drug Category: Enzyme Replacement Agents
Drug Type: Biotech; Approved
Other Brand Names containing Dornase Alfa: Dilor; Dilor-400; Lufyllin; Lufyllin-400; Neothylline; Pulmozyme (Genentech Inc);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: Not Available
Dosage Forms of Pulmozyme (Genentech Inc): Solution Respiratory (inhalation)
Chemical IUPAC Name: Human deoxyribonuclease I
Chemical Formula: C1321H1999N339O396S9
Dornase Alfa on Wikipedia: https://en.wikipedia.org/wiki/Dornase_alfa
Organisms Affected: Humans and other mammals